Cytokine blocking agents in dermatology

Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

1986 • 7,504 citations

Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

2001 • 3,631 citations

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

2000 • 1,463 citations

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

2001 • 913 citations

Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.

1993 • 837 citations

Demyelination occurring during anti-tumor necrosis factor ? therapy for inflammatory arthritides

2001 • 813 citations

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1993 • 714 citations

Control of scarring in adult wounds by neutralising antibody to transforming growth factor β

1992 • 624 citations

Neutralising antibody to TGF-β1,2 reduces cutaneous scarring in adult rodents

1994 • 499 citations

Overexpression of IL-10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity reactions.

1995 • 274 citations

Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions

2000 • 228 citations

Hidradenitis Suppurativa and Crohn's Disease: Response to Treatment with Infliximab

2001 • 163 citations

Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.

2001 • 157 citations

Treatment of psoriatic arthritis with antitumour necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate

2001 • 146 citations

Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency--possible immunologic and clinical consequences

1996 • 146 citations

Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibody

2001 • 137 citations

T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells

1994 • 136 citations

Cytokines in Behçet's disease.

1996 • 133 citations

Remission of Behcet's syndrome with tumour necrosis factor alpha blocking therapy

2001 • 115 citations

Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy

2002 • 105 citations

Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor α antagonist etanercept

2002 • 101 citations

Infliximab (Anti–Tumor Necrosis Factor α Antibody)

2001 • 90 citations

Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate

2001 • 76 citations

Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-α receptor fusion protein

2001 • 64 citations

Role of tumor necrosis factor-α in Sneddon-Wilkinson subcorneal pustular dermatosis

1991 • 60 citations

Remission of Behcet's syndrome with TNFalpha blocking treatment

2002 • 59 citations

Polymyalgia rheumatica and pericardial tamponade

2002 • 19 citations